



Celgene Corporation
Investor Relations Department
86 Morris Avenue
Summit, NJ 07901
United States

[Visit IR website](#)
[Sign-up for e-mail alerts](#)

NASDAQ: CELG

Last Trade:	130.85
Trade Time:	4:15 PM ET Jun 27, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	96.93 - 135.18
Volume	378

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID®, VIDAZA®, THALOMID®, POMALYST®/IMNOVID®, ABRAXANE®, OTEZLA® and ISTODAX®. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These candidates include our IMiDs... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Jun 22, 2017

[Celebrated Photographer Martin Schoeller Shines a Light on People With Psoriatic Disease Including Olympic Swimmer and Author Dara Torres as Part of Celgene's SHOW MORE OF YOU Campaign](#)

Jun 19, 2017

[Celgene Announces Clinical Data Evaluating Broad Range of Blood Cancers to Be Presented at EHA 2017](#)

Jun 17, 2017

[Updated Data from Phase IIIb MAGNIFY Study of REVLIMID \(lenalidomide\) and Rituximab Combination \(R2\) Show Clinical Activity and Responses in Relapsed/Refractory Follicular and Marginal Zone Lymphoma](#)

Jun 14, 2017

[Phase 2a Safety and Efficacy Data Support Further Development of Oral CC-220 in Patients with Lupus](#)

Jun 6, 2017

[Updated Data from Phase 1 Trial of Oral IDHIFA® \(enasidenib\) Demonstrate Complete Responses and Duration of Response in Patients with Relapsed or Refractory AML and an IDH2 Mutation](#)

Financials [\[View all \]](#)

Feb 10, 2017

[Annual Report \(10-K\)](#)

Apr 27, 2017

[Proxy Statement \(DEF 14A\)](#)

Apr 27, 2017

[Quarterly Report \(10-Q\)](#)

Oct 27, 2016

[Quarterly Report \(10-Q\)](#)

Jul 28, 2016

[Quarterly Report \(10-Q\)](#)

